Search Results for keywords:"Exclusive Patent License"

The National Institutes of Health (NIH) is considering giving EpifiZa Inc., a company based in Canada, an exclusive license for some of its patented technologies. These inventions involve fusion proteins aimed at treating people with short stature due to genetic conditions. Public comments and license applications are being accepted until February 9, 2021. The license is intended to cover worldwide use, focusing on developing and selling treatments for growth-related disorders.

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS), is planning to grant an exclusive license to StraightLine Bio, Inc. for certain anti-cancer inventions. These inventions involve patents related to T cell receptors targeting a cancer antigen called KK-LC-1, which is found in certain epithelial cancers. The proposed license would allow StraightLine Bio to develop and commercialize therapies using this technology worldwide, but with some specific exclusions. The public has a chance to comment or object to this plan until December 26, 2024.

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Kyverna Therapeutics for technology involving chimeric antigen receptors (CARs) that target the CD19 protein. This technology is aimed at creating a treatment for autoimmune diseases using a patient’s own altered T lymphocytes. The license could cover worldwide territories and would allow Kyverna to develop, produce, and market this therapy. Public comments or objections about the patent license need to be submitted by March 5, 2021.

The National Institutes of Health is considering granting an Exclusive Patent License to Iovance Biotherapeutics, Inc. for inventions related to cancer treatment. This involves patents for a combination of T cell therapy and vaccination designed to boost the immune system's ability to fight cancer. The proposed license will cover the development and commercialization of these treatments for human cancer patients. The public can submit comments or objections to this proposal by December 17, 2024.

The National Cancer Institute, part of the National Institutes of Health, is considering giving Iovance Biotherapeutics, Inc. an exclusive patent license. This license would allow Iovance to develop and sell specific cancer treatment products using a patented method involving engineered cells that could improve anti-tumor action. Interested parties have until March 12, 2021, to submit comments or objections. This license could cover worldwide rights and mainly focuses on treating several types of cancers, excluding certain specific methods.

The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Kyverna Therapeutics. This license would allow Kyverna to use certain patented inventions to develop a therapy using chimeric antigen receptors (CAR) targeting CD19 for treating autoimmune diseases. The CAR technology uses CRISPR/Cas9-edited T cells to recognize and attack cells expressing the CD19 protein, potentially offering a new treatment option for diseases such as lupus nephritis. Comments or objections to this proposed license must be submitted by March 5, 2021.